Podcast

Rebecca Kirch, JD, shares the latest updates in legislative activism and the concerns of administrative burden and an "identity crisis" in palliative care.
Tripp Logan, PharmD, discusses the challenges community pharmacists face with patient adherence and improving oncology care value.
Priti Shah and Anne Travis, MD, discuss Wolters Kluwer’s latest real-time resource, UpToDate Advanced, designed to help standardize clinical decision-making and reduce costs.
Ronney Abaza, MD, shares the applicability and challenges of using clinical pathways for robotic surgical procedures in urologic cancers.
J Russell Hoverman, MD, PhD, discusses the details of the US Oncology Network implementation of a pilot program to prepare for participation in the Oncology Care Model.
Timothy Showalter, MD, discusses why brachytherapy is being used less and less for the treatment of cervical cancer and the importance of incentivizing quality care in payment policies.
Matthew Davids, MD, discusses the novel agents available for the treatment of chronic lymphocytic leukemia as well as strategies for sequencing monotherapies and administering combination regimens in this disease setting.
Journal of Clinical Pathways spoke with Natalie S Callander, MD, department of hematology and oncology, University of Wisconsin Cancer Center, about her presentation at the latest NCCN Congress on Hematologic Malignancies regarding individualized treatment for patients with relapsed or refractory multiple myeloma.
Journal of Clinical Pathways spoke with Lucio N Gordan, MD, medical director in the division of quality and informatics, Florida Cancer Specialists and Research Institute, regarding his recent report for the Community Oncology Alliance and the implications that setting has on cost of cancer for patients.
Journal of Clinical Pathways spoke with Ray Page, DO, PhD, medical oncologist and hematologist,The Center for Cancer and Blood Disorders (Fort Worth, TX) and Abby Wright, Senior Director of Reimbursement, Biodesix, regarding the importance of prognostic tests—such as Veristrat for lung cancer—in clinical pathways and in aiding achievement of quality measures in the Oncology Care Model.